Keyphrases
Adenovirus
28%
AIDS/HIV
42%
Anti-influenza
14%
Anti-RSV Activity
14%
Anti-SARS-CoV-2
14%
Antibody Expression
28%
Antibody Prophylaxis
14%
Antiviral Gene Therapy
14%
Attractive Alternatives
14%
CD4+ T Cells
50%
Cellular Targets
42%
Co-delivery
42%
Continuous Production
14%
COVID-19
42%
Disease Treatment
14%
Dose Effect
14%
Effector Responses
14%
Enhancer of Zeste Homolog 2 (EZH2)
42%
Exhausted Phenotype
42%
HIV Reservoir
32%
Immune Evasion
42%
Immunocompromised Patients
14%
Immunocompromised Population
14%
Influenza
28%
Influenza Prophylaxis
42%
Intramuscular Injection
14%
Intramuscularly
14%
Long-term Prophylaxis
14%
MHC Class II
32%
Monoclonal Antibody
28%
Nirsevimab
14%
Overexpression
21%
Physiologically Relevant
14%
Preventive Vaccine
14%
Redirector
14%
Reservoir Formation
42%
RSV Prophylaxis
42%
SARS-CoV-2 Infection
14%
Serotype 8
28%
Severe Course
14%
Tazemetostat
42%
TCR Bias
42%
Vaccine Response
42%
Vectored Immunoprophylaxis
14%
Viral Replication
14%
Viral Vectors
14%
Virus Control
42%
Virus Serotype
28%
Xenograft Mouse Model
53%
Yellow Fever
42%
Immunology and Microbiology
Adeno Associated Virus
17%
Adoptive Immunity
6%
Allele
6%
Antigen Specificity
10%
B Cell
15%
CD19
15%
CD4
11%
Cell Killing
9%
Cytotoxic T Cell
73%
Cytotoxic T-Cell
100%
down Regulation
6%
Epitope
26%
Human Immunodeficiency Virus
85%
Human Immunodeficiency Virus 1
20%
Human Immunodeficiency Virus Infection
6%
Immune Evasion
42%
Immunocompromised Patient
8%
Immunotherapy
63%
In Vitro
10%
Influenza
42%
Major Histocompatibility Complex
18%
Monoclonal Antibody
17%
Mouse Model
48%
Nirsevimab
8%
NS4B
6%
Respiratory Syncytial Virus
42%
Serotype
17%
Severe Acute Respiratory Syndrome Coronavirus 2
42%
T Cell
16%
T Cell Receptor
42%
T-Helper Cell
35%
Target Cell
27%
Transcription Factor EZH2
42%
Viral Replication
9%
Viral Vector
8%
Xenograft
48%
Yellow Fever
60%
Yellow Fever Vaccine
6%
Medicine and Dentistry
Adeno-Associated Virus
17%
BIM Protein
5%
Combination Therapy
8%
Cytotoxic T-Cell
42%
down Regulation
5%
Gene Therapy
8%
Human Immunodeficiency Virus
42%
Human Immunodeficiency Virus Infection
5%
Immune Evasion
42%
Immunocompromised Patient
8%
Immunoprophylaxis
8%
In Vitro
5%
Intramuscular Injection
8%
Major Histocompatibility Complex
16%
Monoclonal Antibody
17%
Nirsevimab
8%
Respiratory Syncytial Virus
42%
Serotype
17%
Severe Acute Respiratory Syndrome Coronavirus 2
42%
T-Helper Cell
21%
Tazemetostat
21%
Transcription Factor EZH2
42%
Virus Replication
5%
Virus Vector
8%
Xenograft
5%
